Hyperfine Q1 revenue rises as commercial engine accelerates

Hyperfine

12/05/2026 21:22

Overview

US health tech firm's Q1 revenue grew 83% yr/yr, beating analyst expectations

Company's net loss narrowed compared to prior yr, with improved gross margin

Company bolstered balance sheet with $15 mln debt financing, extending cash runway into 2028

Outlook

Company continues to expect 2026 revenue of $20 mln to $22 mln

Company maintains 2026 cash burn forecast at $26 mln to $28 mln

Result Drivers

COMMERCIAL MOMENTUM - Co said revenue growth was driven by an accelerating commercial engine and increased adoption in office and hospital markets

REGULATORY AND CLINICAL MILESTONES - Co cited international regulatory clearances and new clinical data as supporting broader adoption of its Swoop system

Company press release: ID:nBw8tf3hwa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
Beat
$3.90 mln
$3.54 mln (3 Analysts)
Q1 EPS
-$0.09
Q1 Net Income
-$8.62 mln
Q1 Operating Expenses
$10.54 mln
Q1 Operating Income
-$8.56 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Hyperfine Inc is $2.00, about 14.3% above its May 11 closing price of $1.75

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)